{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:46:27Z","timestamp":1793317587017,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s11914-019-00502-4","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:20:38Z","timestamp":1547770838000},"page":"8-15","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Stopping Denosumab"],"prefix":"10.1007","volume":"17","author":[{"given":"Olivier","family":"Lamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9reng\u00e8re","family":"Aubry-Rozier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Gonzalez","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"key":"502_CR1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"8","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;8:756\u201365.","journal-title":"N Engl J Med"},{"key":"502_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513\u201323.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"502_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"38","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;38:433\u201343.","journal-title":"Lancet"},{"issue":"2","key":"502_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"Paul D. Miller","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewiecki EM, et al ; Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008;43:222\u20139.","journal-title":"Bone"},{"key":"502_CR5","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"\u2022\u2022 Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turn-over markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96:972\u201380 A well-detailed study on the biological and densitometric rebound effect at denosumab discontinuation.","journal-title":"J Clin Endocrinol Metab."},{"key":"502_CR6","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. 2017;28:1723\u201332.","journal-title":"Osteoporos Int"},{"key":"502_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00223-018-0394-4","volume":"103","author":"AW Popp","year":"2018","unstructured":"Popp AW, Varathan N, Buffat H, Senn C, Perrelet R, Lippuner K. Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis. Calcif Tissue Int. 2018;103:50\u20134.","journal-title":"Calcif Tissue Int"},{"key":"502_CR8","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","volume":"27","author":"B Aubry-Rozier","year":"2016","unstructured":"Aubry-Rozier B, Stoll D, Gonzalez Rodriguez E, Lamy O. Severe spontaneous vertebral fractures after denosumab discontinuation: 3 cases reports. Osteoporos Int. 2016;27:1923\u20135.","journal-title":"Osteoporos Int"},{"key":"502_CR9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2016-3170","volume":"102","author":"O Lamy","year":"2017","unstructured":"Lamy O, Stoll D, Gonzalez-Rodriguez E, Hans D, Aubry-Rozier B. Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report. J Clin Endocrin Metab. 2017;102:354\u20138.","journal-title":"J Clin Endocrin Metab"},{"key":"502_CR10","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"\u2022\u2022 Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 2017;32:1291\u20136 The largest published observational study describing the characteristics of patients with multiple vertebral fractures after denosumab discontinuation.","journal-title":"J Bone Miner Res"},{"key":"502_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00223-018-0389-1","volume":"103","author":"L Tripto-Shkolnik","year":"2018","unstructured":"\u2022 Tripto-Shkolnik L, Rouach V, Marcus Y, Rotman-Pikielny P, Benbassat C, Vered I. Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates. Calcif Tissue Int. 2018;103:44\u20139 An observational study that questioned the efficacy of bisphosphonates prescribed before denosumab to avoid the rebound effect upon discontinuation.","journal-title":"Calcif Tissue Int"},{"key":"502_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"\u2022\u2022 Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33:190\u20138 Post hoc analysis of a randomized trial that describes the high incidence of multiple vertebral fractures at denosumab discontinuation, despite very short follow-up.","journal-title":"J Bone Miner Res"},{"key":"502_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Gua\u00f1abens N, et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11\u20137.","journal-title":"Bone"},{"key":"502_CR14","first-page":"w14484","volume":"147","author":"C Meier","year":"2017","unstructured":"Meier C, Uebelhart B, Aubry-Rozier B, et al. Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO\/ASCO. Swiss Med Wkly. 2017 Sep 5;147:w14484.","journal-title":"Swiss Med Wkly"},{"issue":"5","key":"502_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jbspin.2017.12.013","volume":"85","author":"Roland Chapurlat","year":"2018","unstructured":"Chapurlat R. Effects and management of denosumab discontinuation. Joint Bone Spine. 2018. \nhttps:\/\/doi.org\/10.1016\/j.jbspin.2017.12.013\n\n.","journal-title":"Joint Bone Spine"},{"key":"502_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","volume":"29","author":"MB Zanchetta","year":"2018","unstructured":"Zanchetta MB, Boailchuk J, Massari F, Silveira F, Bogado C, Zanchetta JR. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study. Osteoporos Int. 2018;29:41\u20134.","journal-title":"Osteoporos Int"},{"key":"502_CR17","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/jbmr.3370","volume":"33","author":"O Lamy","year":"2018","unstructured":"Lamy O, Gonzalez-Rodriguez E. Underestimation of vertebral fractures after denosumab discontinuation. J Bone Miner Res. 2018;33:547.","journal-title":"J Bone Miner Res"},{"key":"502_CR18","unstructured":"Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, Hans D, Lamy O. Clinical features of 35 patients with 172 spontaneous vertebral fractures after denosumab discontinuation: a single center observational study. Osteoporos Int. 2018;(suppl 1):P637."},{"key":"502_CR19","doi-asserted-by":"crossref","unstructured":"Fernandez E, Benavent D, Bonilla G, Monjo I, Garcia S, Bernad M, et al. Rebound-associated multiple vertebral fractures after discontinuation of denosumab: nine cases report. Ann Rheum Dis. 2018;(suppl):A450.","DOI":"10.1136\/annrheumdis-2018-eular.7046"},{"key":"502_CR20","doi-asserted-by":"crossref","unstructured":"Florez H, Ramirez J, Monegal A, Guanabens N, Peris P. Spontaneous vertebral fractures after denosumab discontinuation: a report of 7 cases. Ann Rheum Dis. 2018;(suppl):A447.","DOI":"10.1136\/annrheumdis-2018-eular.4896"},{"key":"502_CR21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1530\/EJE-16-1027","volume":"176","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Yavropoulou MP, Makras P, Sakellariou GT, Papadopoulou F, Gerou S, et al. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol. 2017;176:677\u201383.","journal-title":"Eur J Endocrinol"},{"key":"502_CR22","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","volume":"27","author":"AW Popp","year":"2016","unstructured":"Popp AW, Zysset PK, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int. 2016;27:1917\u201321.","journal-title":"Osteoporos Int"},{"key":"502_CR23","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00198-016-3886-y","volume":"28","author":"A Modi","year":"2017","unstructured":"Modi A, Sajjan S, Insinga R, Weaver J, Lewiecki EM, Harris ST. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years. Osteoporos Int. 2017;28:1355\u201363.","journal-title":"Osteoporos Int"},{"key":"502_CR24","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1359\/JBMR.040305","volume":"19","author":"PJ Bekker","year":"2004","unstructured":"Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19:1059\u201366.","journal-title":"J Bone Miner Res"},{"key":"502_CR25","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","volume":"28","author":"B Uebelhart","year":"2017","unstructured":"Uebelhart B, Rizzoli R, Ferrari SL. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. Osteoporos Int. 2017;28:2701\u20135.","journal-title":"Osteoporos Int"},{"key":"502_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","volume":"101","author":"IR Reid","year":"2017","unstructured":"Reid IR, Horne AM, Mihov B, Gamble GD. Bone loss after denosumab: only partial protection with zoledronate. Calcif Tissue Int. 2017;101:371\u20134.","journal-title":"Calcif Tissue Int"},{"key":"502_CR27","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1007\/s00198-017-4108-y","volume":"28","author":"T Lehmann","year":"2017","unstructured":"\u2022 Lehmann T, Aeberli D. Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures. Osteoporos Int. 2017;28:3067\u20138 Switching from denosumab to zoledronic acid may have a protective effect on vertebral fractures.","journal-title":"Osteoporos Int."},{"key":"502_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00223-018-0404-6","volume":"103","author":"AM Horne","year":"2018","unstructured":"Horne AM, Mihov B, Reid IR. Bone loss after romosozumab\/denosumab: effects of bisphosphonates. Calcif Tissue Int. 2018;103:55\u201361.","journal-title":"Calcif Tissue Int"},{"key":"502_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","volume":"98","author":"BZ Leder","year":"2017","unstructured":"Leder BZ, Tsai JN, Jiang LA, Lee H. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the Denosumab and Teriparatide Follow-up study (DATA-Follow-up). Bone. 2017;98:54\u20138.","journal-title":"Bone"},{"key":"502_CR30","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","volume":"87","author":"PD Delmas","year":"2002","unstructured":"Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87:3609\u201317.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR31","first-page":"488","volume":"35","author":"JA Eisman","year":"2008","unstructured":"Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol. 2008;35:488\u201397.","journal-title":"J Rheumatol"},{"key":"502_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1359\/JBMR.040920","volume":"20","author":"CJ Rosen","year":"2005","unstructured":"Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005;20:141\u201351.","journal-title":"J Bone Miner Res"},{"key":"502_CR33","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653\u201361.","journal-title":"N Engl J Med"},{"key":"502_CR34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1024\/1661-8157\/a002997","volume":"107","author":"O Lamy","year":"2018","unstructured":"Lamy O, Gonzalez-Rodrigez E, Stoll D, Aubry-Rozier B, Livio F. Multiple vertebral fractures after denosumab discontinuation: how to avoid them? Praxis. 2018;107:649\u201354.","journal-title":"Praxis"},{"key":"502_CR35","doi-asserted-by":"crossref","unstructured":"McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821\u201331.","DOI":"10.1056\/NEJMoa044459"},{"key":"502_CR36","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015;386:1147\u201355.","journal-title":"Lancet"},{"key":"502_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-018-0436-y","volume":"103","author":"E Tsourdi","year":"2018","unstructured":"Tsourdi E, Zillikens C. Certainties and uncertainties about denosumab discontinuation. Calcif Tissue Int. 2018;103:1\u20134.","journal-title":"Calcif Tissue Int"}],"updated-by":[{"DOI":"10.1007\/s11914-020-00565-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000}}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-019-00502-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-019-00502-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-019-00502-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T05:19:57Z","timestamp":1580447997000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-019-00502-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["502"],"URL":"https:\/\/doi.org\/10.1007\/s11914-019-00502-4","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,18]]},"assertion":[{"value":"18 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author Elena Gonzalez Rodriguez is not properly referenced in PubMed. The reference shows as \u201cRodriguez E.G.\u201d, but should be \u201cGonzalez Rodriguez E.\u201d.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Olivier Lamy, Delphine Stoll, B\u00e9reng\u00e8re Aubry-Rozier, and Elena Gonzalez Rodriguez declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}